Skip to main content
Premium Trial:

Request an Annual Quote

Clarification: In the article Will the Private Sector Fulfill Promises or Provide HUPO with Opportunity in 2002? published in the January 7, 2002, issue of ProteoMonitor

Premium

Clarification: In the article “Will the Private Sector Fulfill Promises or Provide HUPO with Opportunity in 2002?” published in the January 7, 2002, issue of ProteoMonitor, a quote from HUPO president Samir Hanash was paraphrased in a way that indicated that he believed companies such as Celera and Myriad Genetics had so far delivered little in the area of proteomics. In a subsequent letter to ProteoMonitor Hanash said that he felt his remarks had been misconstrued, and that by indicating that he believed companies such as Celera and Myriad Genetics had delivered little the article implied that he knows they have accomplished little. Hanash said, with regard to Celera and Myriad: “I do not know what they have accomplished and ... so I could not possibly have said that I know they have accomplished very little. I have the highest regards for the effort that Celera has put out and for the people associated with it.”

Hanash said that it was not his intention to disparage the proteomics efforts of private sector companies, but “to defend the legitimate contributions that academia could make in proteomics” and to point out “that the field is much bigger than any group could deliver no matter how ambitious they are.”

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.